BACKGROUND: Higher levels of physical activity are associated with lower colorectal carcinoma incidence and mortality, perhaps through influencing energy balance, cellular prosta7 systemic inflammation. Although evidence suggests interactive effects of energetics, sedentary lifestyle, and tumor CTNNB1 (β-catenin) or CDKN1B (p27) status on colon cancer prognosis, interactive effects of physical activity and tumor PTGS2 (the official symbol for COX-2) status on clinical outcome remain unknown. METHODS: Using molecular pathological epidemiology database of 605 stage I-III colon and rectal cancers in two prospective cohort studies (the Nurse's Health Study and the Health Professionals Follow-up Study), we examined patient survival according to postdiagnosis physical activity and tumor PTGS2 status (with 382 PTGS2-positive and 223 PTGS2-negative tumors by immunohistochemistry). Cox proportional hazards models were used to calculate colorectal cancer-specific mortality HR, adjusting for clinical and other tumor variables including microsatellite instability status. RESULTS: Among PTGS2-positive cases, compared with the least active first quartile, the multivariate HRs (95% confidence interval) were 0.30 (0.14-0.62) for the second, 0.38 (0.20-0.71) for the third, and 0.18 (0.08-0.41) for the fourth quartile of physical activity level (Ptrend = 0.0002). In contrast, among PTGS2-negative cases, physical activity level was not significantly associated with survival (Ptrend = 0.84; Pinteraction = 0.024, between physical activity and tumor PTGS2 status). CONCLUSIONS: Postdiagnosis physical activity is associated with better survival among patients with PTGS2-positive tumors but not among patients with PTGS2-negative tumors. IMPACT: Immunohistochemical PTGS2 expression in colorectal carcinoma may serve as a predictive biomarker in pathology practice, which may predict stronger benefit from exercise.
BACKGROUND: Higher levels of physical activity are associated with lower colorectal carcinoma incidence and mortality, perhaps through influencing energy balance, cellular prosta7 systemic inflammation. Although evidence suggests interactive effects of energetics, sedentary lifestyle, and tumorCTNNB1 (β-catenin) or CDKN1B (p27) status on colon cancer prognosis, interactive effects of physical activity and tumorPTGS2 (the official symbol for COX-2) status on clinical outcome remain unknown. METHODS: Using molecular pathological epidemiology database of 605 stage I-III colon and rectal cancers in two prospective cohort studies (the Nurse's Health Study and the Health Professionals Follow-up Study), we examined patient survival according to postdiagnosis physical activity and tumorPTGS2 status (with 382 PTGS2-positive and 223 PTGS2-negative tumors by immunohistochemistry). Cox proportional hazards models were used to calculate colorectal cancer-specific mortality HR, adjusting for clinical and other tumor variables including microsatellite instability status. RESULTS: Among PTGS2-positive cases, compared with the least active first quartile, the multivariate HRs (95% confidence interval) were 0.30 (0.14-0.62) for the second, 0.38 (0.20-0.71) for the third, and 0.18 (0.08-0.41) for the fourth quartile of physical activity level (Ptrend = 0.0002). In contrast, among PTGS2-negative cases, physical activity level was not significantly associated with survival (Ptrend = 0.84; Pinteraction = 0.024, between physical activity and tumorPTGS2 status). CONCLUSIONS: Postdiagnosis physical activity is associated with better survival among patients with PTGS2-positive tumors but not among patients with PTGS2-negative tumors. IMPACT: Immunohistochemical PTGS2 expression in colorectal carcinoma may serve as a predictive biomarker in pathology practice, which may predict stronger benefit from exercise.
Authors: Elizabeth A Hibler; Chengcheng Hu; Peter W Jurutka; Maria E Martinez; Elizabeth T Jacobs Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-12-05 Impact factor: 4.254
Authors: Mai Yamauchi; Teppei Morikawa; Aya Kuchiba; Yu Imamura; Zhi Rong Qian; Reiko Nishihara; Xiaoyun Liao; Levi Waldron; Yujin Hoshida; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino Journal: Gut Date: 2012-03-17 Impact factor: 23.059
Authors: Toshinori Hinoue; Daniel J Weisenberger; Christopher P E Lange; Hui Shen; Hyang-Min Byun; David Van Den Berg; Simeen Malik; Fei Pan; Houtan Noushmehr; Cornelis M van Dijk; Rob A E M Tollenaar; Peter W Laird Journal: Genome Res Date: 2011-06-09 Impact factor: 9.043
Authors: Christie Eheman; S Jane Henley; Rachel Ballard-Barbash; Eric J Jacobs; Maria J Schymura; Anne-Michelle Noone; Liping Pan; Robert N Anderson; Janet E Fulton; Betsy A Kohler; Ahmedin Jemal; Elizabeth Ward; Marcus Plescia; Lynn A G Ries; Brenda K Edwards Journal: Cancer Date: 2012-03-28 Impact factor: 6.860
Authors: Nicholas J Ollberding; Iona Cheng; Lynne R Wilkens; Brian E Henderson; Michael N Pollak; Laurence N Kolonel; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-02-21 Impact factor: 4.254
Authors: Peter M Rothwell; Michelle Wilson; Jacqueline F Price; Jill F F Belch; Tom W Meade; Ziyah Mehta Journal: Lancet Date: 2012-03-21 Impact factor: 79.321
Authors: Mai Yamauchi; Paul Lochhead; Teppei Morikawa; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino Journal: Gut Date: 2012-04-05 Impact factor: 23.059
Authors: Veronika Fedirko; Elio Riboli; Anne Tjønneland; Pietro Ferrari; Anja Olsen; H Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; Teresa Norat; Eugène H J M Jansen; Christina C Dahm; Kim Overvad; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Antoine Racine; Annekatrin Lukanova; Birgit Teucher; Heiner Boeing; Krasimira Aleksandrova; Antonia Trichopoulou; Vassiliki Benetou; Dimitrios Trichopoulos; Sara Grioni; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Peter D Siersema; Petra H Peeters; Guri Skeie; Magritt Brustad; Maria-Dolores Chirlaque; Aurelio Barricarte; Jose Ramón Quirós; Maria José Sánchez; Miren Dorronsoro; Catalina Bonet; Richard Palmqvist; Göran Hallmans; Timothy J Key; Francesca Crowe; Kay-Tee Khaw; Nick Wareham; Isabelle Romieu; James McKay; Petra A Wark; Dora Romaguera; Mazda Jenab Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-01-25 Impact factor: 4.254
Authors: Lee W Jones; Marilyn L Kwan; Erin Weltzien; Sarat Chandarlapaty; Barbara Sternfeld; Carol Sweeney; Philip S Bernard; Adrienne Castillo; Laurel A Habel; Candyce H Kroenke; Bryan M Langholz; Charles P Queensberry; Chau Dang; Britta Weigelt; Lawrence H Kushi; Bette J Caan Journal: Cancer Res Date: 2016-08-03 Impact factor: 12.701
Authors: Raaj S Mehta; Dawn Q Chong; Mingyang Song; Jeffrey A Meyerhardt; Kimmie Ng; Reiko Nishihara; Zhirong Qian; Teppei Morikawa; Kana Wu; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino; Andrew T Chan Journal: Gastroenterology Date: 2015-05-27 Impact factor: 22.682
Authors: Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino Journal: Am J Gastroenterol Date: 2014-06-17 Impact factor: 10.864
Authors: NaNa Keum; Ying Bao; Stephanie A Smith-Warner; John Orav; Kana Wu; Charles S Fuchs; Edward L Giovannucci Journal: JAMA Oncol Date: 2016-09-01 Impact factor: 31.777
Authors: Akiko Hanyuda; Sun A Kim; Alejandro Martinez-Fernandez; Zhi Rong Qian; Mai Yamauchi; Reiko Nishihara; Teppei Morikawa; Xiaoyun Liao; Kentaro Inamura; Kosuke Mima; Yin Cao; Xuehong Zhang; Kana Wu; Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Ramesh A Shivdasani; Shuji Ogino Journal: Ann Surg Oncol Date: 2015-11-17 Impact factor: 5.344